ArticleIranian journal of child neurology2024
Lacosamide as an Adjunctive Therapy in Drug-Resistant Absence Epilepsy: Successful Treatment of Four Patients.
Article in Iranian journal of child neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Absence epilepsy is one of the most common epileptic syndromes in children, and despite its benign nature, a percentage of these children are drug-resistant. This study presents four cases of drug-resistant absence epilepsy in children who were unresponsive to traditional antiepileptic drugs. The study reports the successful use of Lacosamide as an adjunctive therapy to completely control symptoms and electroencephalogram (EEG) abnormalities. The patients, aged four to ten years, had previously failed treatment with Ethosuximide, Sodium Valproate, Levetiracetam, and Topiramate in various combinations. Lacosamide was initiated at a dose of 10 mg/kg per day in combination with Sodium valproate, resulting in rapid and sustained improvement. The patients remained symptom-free and showed no EEG abnormalities for one to two years. These findings suggest that Lacosamide can be considered a safe add-on drug for refractory absence epilepsy. However, it may be contended that additional confirmatory trials are necessary to investigate the effects of Lacosamide in a larger patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.